<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        148-11-02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZOMETA 4MG VIAL\5ML
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ZOLEDRONIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        792.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M05BA08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.what is Zometa:</strong></p><p>-&nbsp;&nbsp; The active substance of Zometa is zoledronic acid. It belongs to a group of medicines called bisphosphonates.</p><p>Zometa is supplied as 4 mg powder and solvent for solution for infusion, or as 4 mg/5 ml concentrate for solution for infusion or as a &ldquo;ready-to-use&rdquo; 4 mg/100 mL solution for infusion.</p><p>Zometa is given as an infusion into a vein.&nbsp;&nbsp;</p><p><strong>b.What is used for: </strong></p><p>Therapeutic indications:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prevent bone complications, e.g. fractures, in adult patients with bone metastases (spread of cancer from primary site to the bone) and to lower the amount of calcium in the blood in patients with tumor-induced hypercalcemia (TIH).</p><p>&nbsp;</p><p><strong>How Zometa works</strong></p><p>Zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change. It is used to reduce the amount of calcium in the blood in cases where it is too high due to the presence of a tumor. Tumors can accelerate normal bone change in such a way that the release of calcium from bone is increased. This condition is known as hypercalcemia of malignancy (HCM).</p><p>In premenopausal women with early breast cancer (EBC) zoledronic acid has anticancer effects in addition to hormonal therapy.</p><p>In postmenopausal women, the levels of estrogen are lower than in premenopausal women. These lowered estrogen levels can cause bone loss. The affected bones break more easily (fracture). Postmenopausal women with early breast cancer can be prescribed aromatase inhibitors to treat their condition. Aromatase inhibitors (medicines to treat breast cancer) further decrease the already low estrogen levels and result in more bone loss, thus increasing the risk of fracture. Zometa is used to prevent bone loss and fractures in this high-risk population.</p><p>Ask your doctor if you have any questions about why this medicine has been prescribed for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all the doctor&rsquo;s instructions carefully. They may differ from the general information contained in this leaflet.</p><p><strong>a. Do not take Zometa</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are</strong> allergic (hypersensitive) to zoledronic acid or other bisphosphonates (the group of substances to which Zometa belongs), or to any of the other ingredients of Zometa listed at the end of this leaflet.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are</strong> pregnant.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are </strong>breast-feeding.</p><p>If any of these applies to you, do not use Zometa and tell your doctor. Ask your doctor if you have any further questions.</p><p><strong>b. Take special care with Zometa</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you had or have a kidney problem.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you had or have pain, swelling or numbness of the jaw or a &ldquo;heavy jaw feeling&rdquo; or loosening of a tooth or any other oral symptoms.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are undergoing dental treatment or will undergo a dental surgery, tell your dentist that you are being treated with Zometa.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you had or have joint stiffness, aches and pains and difficulty in movement (especially of the hip or thigh) or pain around the external ear canal, tell your doctor, as this may be a sign of a bone problem called osteonecrosis (damage to bone tissue due to loss of blood supply to the bone).</p><p>You are advised to have a dental examination prior to treatment with Zometa and should avoid invasive dental procedures during treatment. Be informed of the importance of good dental hygiene, routine dental care and regular dental check-ups.&nbsp; Immediately report any oral symptoms, such as loosening of a tooth, pain, swelling, or non-healing of sores or discharge during treatment with Zometa.</p><p>Your doctor will check your response to treatment at regular intervals. He or she must perform blood tests prior to your treatment with Zometa.</p><p>Ensure sufficient intake of liquids prior to infusions as directed by your doctor as this will help prevent dehydration.</p><p>If you are being treated with Aclasta&reg;, a medicine which contains the same active substance as Zometa or with any another bisphosphonates (same class of drug), you should not be treated with Zometa concomitantly.</p><p>If any of these apply to you, <strong>tell your doctor before you are given Zometa.</strong></p><p>Reduced levels of calcium in the blood (hypocalcemia), sometimes leading to muscle cramps, dry skin, burning sensation, have been reported in patients treated with Zometa. Irregular heart beat (cardiac arrhythmia), seizures, spasm and twitching (tetany) have been reported as secondary to severe hypocalcemia. In some instances, the hypocalcemia may be life-threatening. If you have pre-existing hypocalcemia, it must be corrected before initiating the first dose of Zometa. You will be given calcium and vitamin D supplements.</p><p>If any of these apply to you,<strong> tell your doctor straight away.</strong></p><p><strong>c. Using other medicines, herbal or dietary supplements</strong></p><p>Tell your doctor, nurse or pharmacist if you are taking or have recently taken any other medicines, including any you have bought without a prescription.</p><p>It is especially important for your doctor to know if you are also taking aminoglycosides (a type of medicine used to treat severe infections), calcitonin (a type of medicine used to treat post-menopausal osteoporosis and hypercalcemia), loop diuretics (a type of medicine to treat high blood pressure or edema), other calcium lowering medicines, since the combination of these with bisphosphonates may cause the calcium level in the blood to become too low. Tell your doctor if you are taking any medicines known to be harmful to your kidneys. Tell your doctor if you are taking anti-angiogenic medicines as part of your cancer treatment because the combination of these medicines with bisphosphonates may increase the risk of bone damage in the jaw (osteonecrosis).</p><p><strong>d.</strong> <strong>Older people (age 65 years and over)</strong></p><p>Zometa can be given to elderly people. There is no evidence to suggest that any additional precautions are needed.</p><p><strong>e. Pregnancy and breast-feeding</strong></p><p>Tell your doctor if you are or think that you may be pregnant. You should not be given Zometa during pregnancy.</p><p>Ask your doctor for advice if you are breast-feeding. It is not known whether zoledronic acid, the active substance of Zometa, passes into the milk. You should not breast-feed during treatment with Zometa.</p><p><strong>f. Children and adolescents: </strong></p><p>Zometa is not recommended for use in adolescents and children below the age of 18 years.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>In adults, the usual dose given is 4 mg. If you have a kidney problem, your doctor may give you a lower dose depending on the severity of your kidney problem.</p><p>&nbsp;</p><p>In adults, Zometa is usually given as an infusion which should last no less than 15 minutes and should be administered as a single intravenous solution in a line separate from all other drugs.</p><p>In addition, if you do not suffer from hypercalcemia you will also receive oral supplementary doses of calcium and vitamin D daily.</p><p><strong>a. If you take more Zometa than you should</strong></p><p>You may develop serum electrolyte abnormalities and changes in kidney function, including severe kidney impairment. If you have received doses higher than those recommended you should be carefully monitored by your physician. Calcium supplementation by infusion may be needed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Like all medicines, some side effects may occur while being treated with Zometa, although not everybody gets them. The most common ones are usually mild and will probably disappear after a short time. The following side effects have been reported:</p><p>If any of the side effects get serious, tell your doctor, nurse or pharmacist.</p><p>In adults with advanced cancer involving bone</p><p>Very common (affecting more than 1 in 10 patients)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of phosphate in the blood.</p><p>Common (affecting less than 1 in 10 patients)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling or numbness of the hands or feet (paresthesia).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure (hypertension).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swollen hands, ankles or feet (peripheral edema).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep disorder.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache and flu-like symptoms consisting of fever, fatigue, weakness, drowsiness, chills and bone, joint and muscle ache.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal reactions such as nausea, vomiting, constipation and loss of appetite.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of red blood cells (anemia).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of calcium in the blood.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone, joint, muscle and generalized pain if you are a pre- or postmenopausal woman treated for early breast cancer, in conjunction with hormonal therapy, you may experience these side effects more frequently.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint stiffness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood test indicating changes in kidney function (higher levels of creatinine).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conjunctivitis, as reported with other bisphosphonates (the group of substances to which Zometa belongs).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive sweating (hyperhidrosis).</p><p>Uncommon (affecting less than 1 in 100 patients)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in the mouth, teeth and jaw, sores or non-healing sores in the mouth or discharge, swelling, dry mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. These could be signs of bone damage in the jaw (osteonecrosis). Tell your doctor and dentist immediately if you experience such symptoms.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in kidney function, including severe kidney impairment. Such changes are also known to occur with other medicines of this kind. In addition, cases of kidney disease have been reported.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity reactions.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin reactions (redness and swelling) at the infusion site, rash, itching.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low counts of white blood cells and blood platelets.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of magnesium and potassium in the blood. Your doctor will monitor these and take necessary measures.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disturbed sense of taste.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trembling.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach discomfort after meal.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight increased.</p><p>Rare (affecting less than 1 in 1,000 patients)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling, mainly of the face and throat.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High level of potassium and sodium in the blood.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heart-beat.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu-like symptoms, including arthritis and joint swelling.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lung disease (interstitial lung disease)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful red and/or swollen eye (uveitis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A disorder of the kidney function called Fanconi syndrome.</p><p>Very rare cases (affecting less than 1 in 10,000 patients)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe bone, joint and muscle pain, occasionally incapacitating.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heart&ndash;beat (cardiac arrhythmia).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures. Tell your doctor immediately if you experience such symptoms.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness (hypoesthesia).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spasm and twitching (tetany). Tell your doctor immediately if you experience such symptoms.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in breathing with wheezing or coughing.</p><p>&bull;</p><p>Irregular heart rhythm (atrial fibrillation) has also been seen in patients receiving zoledronic acid for postmenopausal osteoporosis. It is currently unclear whether zoledronic acid causes this irregular heart rhythm, but you should report it to your doctor if you experience such symptoms after you have received zoledronic acid.</p><p>Other bisphosphonates can cause breathing difficulties in patients with asthma, who are allergic to aspirin. No such cases have been reported with Zometa, however.</p><p>Unusual fracture of the thigh bone, particularly in patients on long-term treatment for osteoporosis may occur. Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early sign of a possible fracture of the thigh bone.</p><p>Consult your doctor or nurse if you notice any other unexpected effects.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use after the expiry date stated on the pack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Don&rsquo;t store above 30&ordm; C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor or nurse knows how to store Zometa properly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp; The active substance of Zometa is zoledronic acid</p><p>It is supplied as a liquid concentrate in a vial. One vial contains 4 mg of zoledronic acid.</p><p>The other ingredients are: mannitol, sodium citrate, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                -   Zometa is supplied as a powder in a vial together with an ampoule of water in which to dissolve the powder or as a liquid concentrate in a vial, which is further diluted prior to use.
Zometa “ready-to-use” presentation is supplied as a bottle.
This information might differ in some countries.
Not all packs may marketed in your country

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d. This leaflet was last approved by Swissmedic in 11/2022.

e. To report any side effect(s):

Saudi Arabia

The National Pharmacovigilance Center (NPC):

o SFDA call center: 19999

o E-mail: npc.drug@sfda.gov.sa

o Website: https://ade.sfda.gov.sa

 

Patient Safety Department Novartis Consulting AG - Saudi Arabia:

o Toll Free Number: 8001240078

o Phone: +996112658100

o Fax: +966112658107

o Email: adverse.events@novartis.com

 

•    Other GCC States:

-  Please contact the relevant competent authority.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>أ.ما هو دواء زوميتا:</strong></p><p dir="RTL">- المادة الفعالة في زوميتا هي حمض الزوليدرونيك. وهو ينتمي إلى مجموعة من الأدوية تُسمى البيسفوسفونات.</p><p dir="RTL">يتم توفير زوميتا على هيئة مسحوق ومذيب 4 مجم لمحلول التسريب، أو كمُركز 4 مجم/5 مل لمحلول التسريب أو على هيئة محلول &quot;جاهز للاستخدام&quot; 4 مجم/100 مل للتسريب.</p><p dir="RTL">يتم إعطاء زوميتا كتسريب في الوريد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ب.دواعي الاستعمال:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوقاية من مضاعفات العظام، مثل الكسور، لدى المرضى البالغين المصابين بنقائل العظام (انتشار السرطان من الموقع الرئيسي إلى العظام) وخفض كمية الكالسيوم في الدم لدى المرضى المصابين بفرط كالسيوم الدم الناجم عن الورم (TIH).</p><p><strong>:</strong><strong> </strong><strong>كيف يعمل زوميتا</strong></p><p>يعمل حمض زوليدرونيك بأن يربط نفسه بالعظام ويبطئ سرعة التغيرات العظمية. وهو يُستعمل لتقليل كمية الكالسيوم في الدم &nbsp;&nbsp;عندما يكون مرتفعاً جداً بسبب وجود ورم. قد تؤدي الأورام إلى زيادة سرعة التغيرات الطبيعية للعظام بما يؤدي إلى زيادة (HCM) انطلاق الكالسيوم من العظام. هذه الحالة تُعرَف باسم فرط كالسيوم الدم الناجم عن الأورام الخبيثة &nbsp;</p><p>&nbsp;(EBC) في النساء قبل سن انقطاع الطمث اللاتي لديهن سرطان مبكر في الثدي &nbsp;</p><p>. يزاول حمض زوليدرونيك آثاراً مضادة للسرطان بالإضافة إلى العلاج الهرموني</p><p>في النساء بعد سن انقطاع الطمث، تكون مستويات الإستروجين أقل منها في النساء قبل سن انقطاع الطمث. هذه المستويات المنخفضة من الإستروجين قد تؤدي إلى فقدان العظم. العظام المصابة تنكسر بسهولة أكبر (كسور) &nbsp;&nbsp;</p><p>النساء بعد سن انقطاع الطمث اللاتي لديهن سرطان مبكر في الثدي يمكن أن يوصف لهن مثبطات الأروماتيز لعلاج حالتهن تؤدي مثبطات الأروماتيز (أدوية تُستعمَل لعلاج سرطان الثدي) إلى مزيد من الخفض لمستويات الإستروجين المنخفضة بالفعل، مما يؤدي إلى مزيد من فقدان العظم، وزيادة مخاطرة حدوث الكسور. يُستعمَل زوميتا لمنع فقدان العظم وحدوث الكسور في هذه الفئة من الناس ذات المخاطرة العالية.</p><p dir="RTL">إذا كانت لديك أي أسئلة عن الكيفية التي يعمل بها زوميتا أو عن سبب وصف هذا الدواء لك، برجاء أن تسأل طبيبك</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع جميع تعليمات الطبيب بعناية. فقد تختلف عن المعلومات العامة الواردة في هذه النشرة.</p><p dir="RTL"><strong>أ. لا تتناول دواء زوميتا في الحالات التالية</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني</strong> من حساسية (فرط حساسية) لحمض الزوليدرونيك أو البيسفوسفونات الأخرى (مجموعة المواد التي تنتمي إليها زوميتا)، أو لأي من المكونات الأخرى لزوميتا المدرجة في نهاية هذه النشرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنتِ</strong> حاملاً.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنتِ</strong> تُرضعين رضاعة طبيعية.</p><p dir="RTL">إذا انطبق عليك أي من هذه الأعراض، فلا تستخدم زوميتا، وأخبر طبيبك بذلك. أسال طبيبك إذا كانت لديك أي أسئلة أخرى.</p><p dir="RTL"><strong>ب. الاحتياطات عند استعمال زوميتا</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني حاليًا أو كنت تعاني من مشاكل في الكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعاني من الالم أو قد كان لديك ألم أو تورم أو تنميل في الفك أو &quot;شعور بثقل في الفك&quot; أو تخلخل في أحد الأسنان أو أي أعراض فموية أخرى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع لعلاج أسنان أو ستخضع لجراحة أسنان، فأخبر طبيب الأسنان بأنك تستعمل دواء زوميتا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني حاليًا أو قد كنت تعاني من تيبس في المفاصل، أو أوجاع وآلام وصعوبة في الحركة (خاصةً في الورك أو الفخذ) أو ألم حول قناة الأذن الخارجية، فأخبر طبيبك بذلك، لأن هذا قد يكون علامة على مشكلة في العظام تُسمى نخر العظام (تلف في أنسجة العظام بسبب فقدان إمداد العظام بالدم).</p><p dir="RTL">يُنصح بإجراء فحص للأسنان قبل تلقي العلاج بزوميتا ويجب عليك تجنب إجراءات الأسنان العميقة أثناء فترة تلقي العلاج بزوميتا. يُرجى الانتباه إلى أهمية الحفاظ على صحة الأسنان، ورعاية الأسنان الروتينية، وفحوصات الأسنان المنتظمة. أبلغ فورًا عن أي أعراض فموية، مثل تخلخل أحد الأسنان، أو الشعور بألم أو تورم، أو عدم شفاء قروح، أو خروج إفرازات أثناء تلقي العلاج بزوميتا.</p><p dir="RTL">سيتحقق طبيبك من استجابتك للعلاج على فترات منتظمة. يجب عليه إجراء اختبارات دم قبل تلقيك العلاج بزوميتا.</p><p dir="RTL">تأكد من تناول كمية كافية من السوائل قبل حقن التسريب وفقًا لتوجيهات طبيبك لأن ذلك سيساعد في وقايتك من الجفاف.</p><p dir="RTL">إذا كنت تستعمل دواء أكلاستا<sup>&reg;</sup>، وهو دواء يحتوي على نفس المادة الفعالة مثل زوميتا أو بأي بيسفوسفونات أخرى (مماثل للعائلة الدوائية)، فيجب عليك عدم تلقي العلاج باستخدام زوميتا في نفس الوقت.</p><p dir="RTL">إذا انطبق عليك أي مما سبق، <strong>فأخبر طبيبك بذلك قبل أن تتلقى زوميتا</strong>.</p><p dir="RTL">تم الإبلاغ عن انخفاض مستويات الكالسيوم في الدم (نقص كالسيوم الدم)، مما أدى أحيانًا إلى تشنجات عضلية، وجفاف الجلد، والشعور بالحرقان، لدى المرضى الذين عولجوا بزوميتا. تم الإبلاغ عن عدم انتظام ضربات القلب (اضطراب النظم القلبي)، ونوبات، وتشنجات، وارتعاش (التكزز) كأعراض ثانوية لنقص كالسيوم الدم الشديد. في بعض الحالات، قد يكون نقص كالسيوم الدم مهددًا للحياة. إذا كنت تعاني من نقص في كالسيوم الدم مسبقًا، فيجب معالجته قبل البدء في تلقي الجرعة الأولى من زوميتا. سيتم إعطاؤك مكملات الكالسيوم وفيتامين د.</p><p dir="RTL">إذا عانيت من أي من هذه الأعراض، <strong>فأخبر طبيبك بذلك على الفور</strong>.</p><p dir="RTL"><strong>ج. التداخلات الدوائية من أخذ زوميتا مع أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الممرضة أو الصيدلي بأي أدوية أخرى تتناولها حالياً &nbsp;أو تناولتها مؤخرًا، بما في ذلك تلك التي حصلت عليها من دون وصفة طبية.</p><p dir="RTL">من المهم بشكل خاص أن يعرف طبيبك إذا كنت تستخدم أيضًا أمينوغليكوزيدات (نوع من الأدوية يُستخدم لعلاج حالات العدوى الشديدة)، والكالسيتونين (نوع من الأدوية يُستخدم لعلاج هشاشة العظام وفرط كالسيوم الدم بعد انقطاع الطمث)، ومدرات البول الحلقية (نوع من الأدوية يُستخدم لعلاج ارتفاع ضغط الدم أو الوذمة)، وأدوية أخرى لخفض الكالسيوم، لأن الجمع بين هذه الأدوية والبيسفوسفونات قد يسبب انخفاضًا شديدًا في مستوى الكالسيوم في الدم. أخبر طبيبك بما إذا كنت تتناول أي أدوية من المعروف أنها ضارة بالكلى. أخبر طبيبك بما إذا كنت تتناول أدوية مضادة لتولد الأوعية كجزء من علاج السرطان لأن الجمع بين هذه الأدوية والبيسفوسفونات قد يُزيد من خطر حدوث تلف العظام في الفك (نخر العظم).</p><p dir="RTL"><strong>د.</strong> <strong>كبار السن (65 عامًا وما فوق)</strong></p><p dir="RTL">يمكن إعطاء زوميتا لكبار السن. لا يوجد دليل يشير إلى الحاجة إلى أي احتياطات إضافية.</p><p dir="RTL"><strong>هـ. الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">أخبري طبيبكِ إذا كنتِ حاملاً أو تعتقدين أنكِ قد تكونين حاملاً. يجب ألا تستخدمي زوميتا أثناء الحمل.</p><p dir="RTL">اسألي طبيبكِ للحصول على الاستشارة إذا كنتِ تُرضعين طبيعيًا. من غير المعروف ما إذا كان حمض الزوليدرونيك، المادة الفعالة في زوميتا، ينتقل إلى الحليب. يجب ألا تُرضعي رضاعة طبيعية خلال فترة العلاج بدواء زوميتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و. الأطفال والمراهقين</strong></p><p dir="RTL">لا ينصح باستخدام زوميتا للأطفال والمراهقين الذين تقل اعمارهم عن 18 عاماً</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">في البالغين، الجرعة المعتادة التي يتم إعطاؤها هي 4 مجم. إذا كنت تعاني من مشكلة في الكلى، فقد يعطيك طبيبك جرعة أقل بناءً على مدى شدة مشكلة الكلى لديك.</p><p dir="RTL">في البالغين، عادةً ما يتم إعطاء زوميتا كتسريب لمدة يجب ألا تقل عن 15 دقيقة ويجب إعطاؤه كمحلول وريدي واحد في خط وريدي منفصل عن جميع العقاقير الأخرى.</p><p dir="RTL">بالإضافة إلى ذلك، إذا لم تكن تعاني من فرط كالسيوم الدم، فستتلقى أيضًا جرعات تكميلية فموية من الكالسيوم وفيتامين د يوميًا.</p><p dir="RTL"><strong>أ. الجرعة الزائدة من زوميتا</strong></p><p dir="RTL">قد تصاب باختلالات في الكتروليتات المصل وتغيرات في وظائف الكلى، بما في ذلك قصور شديد في الكلى. إذا كنت قد تلقيت جرعات أعلى من تلك الموصى بها، فيجب أن تخضع لمراقبة دقيقة من قِبل طبيبك. قد تكون هناك حاجة إلى إعطائك مكملات الكالسيوم عن طريق التسريب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- مثل جميع الأدوية، قد تحدث بعض الآثار الجانبية أثناء العلاج بزوميتا، على الرغم من أنها لا تصيب الجميع. وعادةً ما تكون الأعراض الجانبية الأكثر شيوعًا خفيفة ومن المحتمل أن تزول بعد فترة قصيرة. تم الإبلاغ عن الأعراض الجانبية التالية:</p><p dir="RTL">إذا تفاقمت أي من الأعراض الجانبية، فأخبر طبيبك أو الممرضة أو الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لدى البالغين المصابين بسرطان متقدم يشمل العظام:</strong></p><p dir="RTL">شائعة جدًا (تصيب أكثر من شخص واحد من كل 10 مرضى)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الفوسفات في الدم.</p><p dir="RTL">شائعة (تصيب أقل من مريض واحد من بين كل 10 مرضى)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو خدر في اليدين أو القدمين (تنميل).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم (فرط ضغط الدم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين أو الكاحلين أو القدمين (وذمة محيطية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب النوم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع وأعراض تشبه أعراض الإنفلونزا تتضمن الحمى، والتعب، والضعف، والنعاس، والقشعريرة، ألم العظام و المفاصل والعضلات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل مَعِدية معوية مثل الغثيان والتقيؤ والإمساك وفقدان الشهية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى خلايا الدم الحمراء (فقر الدم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الكالسيوم في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العظام والمفاصل والعضلات وألم عام، وإذا كنتِ امرأة في مرحلة ما قبل انقطاع الطمث أو بعده وتمت معالجتكِ من سرطان الثدي المبكر بالتزامن مع العلاج الهرموني، فقد تعانين من هذه الأعراض الجانبية بشكل أكثر تكرارًا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس المفاصل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبار دم تشير نتائجه إلى وجود تغيرات في وظائف الكلى (ارتفاع مستويات الكرياتينين).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الملتحمة، كما تم الإبلاغ عنه عند استخدام البيسفوسفونات الأخرى (مجموعة المواد التي تنتمي إليها زوميتا).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرق مفرط (فرط التعرق).</p><p dir="RTL">غير شائعة (تصيب أقل من مريض واحد من بين كل 100 مريض)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الفم والأسنان والفك، أو قروح أو قروح غير ملتئمة في الفم أو إفرازات، أو تورم، أو جفاف الفم، أو تنميل، أو شعور بثقل في الفك، أو تخلخل أحد الأسنان. قد تكون هذه علامات على تلف العظام في الفك (نخر العظم). أخبر طبيبك وطبيب الأسنان على الفور بما إذا عانيت من مثل هذه الأعراض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في وظائف الكلى، بما في ذلك قصور شديد في الكلى. ومن المعروف أيضًا أن هذه التغيرات تحدث مع أدوية أخرى من هذا النوع. بالإضافة إلى ذلك، تم الإبلاغ عن حالات مرض الكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل فرط الحساسية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل جلدية (احمرار وتورم) في موضع التسريب، طفح جلدي، حكة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء والصفائح الدموية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى المغنيسيوم والبوتاسيوم في الدم. سيراقب طبيبك هذه الأعراض الجانبية ويتخذ التدابير اللازمة حيالها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب حاسة التذوق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضبابية الرؤية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم البطن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة بعد تناول الطعام.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن.</p><p dir="RTL">نادرة (تؤثر على أقل من مريض واحد من بين كل 1000 مريض)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه والحلق بشكل أساسي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى البوتاسيوم والصوديوم في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء ضربات القلب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض شبيهة بأعراض الإنفلونزا، بما في ذلك التهاب المفاصل وتورم المفاصل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض بالرئة (مرض الرئة الخلالي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار و/أو تورم مؤلم بالعين (التهاب العنبية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في وظائف الكلى يُسمى متلازمة فانكوني.</p><p dir="RTL">حالات نادرة جدًا (تصيب أقل من مريض واحد من بين كل 10000 مريض)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد وأحيانًا يعيق الحركة في العظام والمفاصل والعضلات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب (اضطراب النظم القلبي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات. أخبر طبيبك على الفور إذا عانيت من مثل هذه الأعراض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنميل (نقص الحس).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنج والارتعاش (التكزز). أخبر طبيبك على الفور بما إذا عانيت من مثل هذه الأعراض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس مصحوبة بأزيز أو سعال.</p><p dir="RTL">كما لوحظ عدم انتظام نظم القلب (الرجفان الأذيني) لدى المريضات اللواتي يتلقين حمض زوليدرونيك لعلاج هشاشة العظام التالية لانقطاع الطمث. من غير الواضح حاليًا ما إذا كان حمض زوليدرونيك يسبب عدم انتظام ضربات القلب هذا، ولكن يجب عليك إبلاغ طبيبك بما إذا عانيت من هذه الأعراض بعد تلقي حمض زوليدرونيك.</p><p dir="RTL">يمكن أن تسبب البيسفوسفونات الأخرى صعوبات في التنفس لدى المرضى المصابين بالربو، الذين يعانون من حساسية تجاه الأسبرين. ومع ذلك، لم يتم الإبلاغ عن مثل هذه الحالات عند تلقي زوميتا.</p><p dir="RTL">قد يحدث كسر غير معتاد في عظم الفخذ، خاصةً لدى المرضى الذين يتلقون علاجًا طويل المدى لهشاشة العظام. اتصل بطبيبك إذا عانيت من ألم أو ضعف أو عدم راحة في فخذك أو وركك أو الأربية لأن هذا قد يكون علامة مبكرة على وجود كسر محتمل في عظم الفخذ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدمه بعد تاريخ انتهاء الصلاحية الموضح على العبوة.</p><p dir="RTL"> لا تخزّنه في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL"> يحفظ زوميتا في العبوة الأصلية.</p><p dir="RTL"> يعرف طبيبك أو ممرضتك كيفية تخزين زوميتا بشكل صحيح.</p><p dir="RTL"> يحفَظ بعيدًا عن متناول ورؤية الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة في زوميتا هي حمض الزوليدرونيك</p><p dir="RTL">يتم توفيره في صورة سائل مُركّز في قنينة. تحتوي القارورة الواحدة على 4 مجم من حمض الزوليدرونيك.</p><p dir="RTL">المكونات الأخرى هي: مانيتول، سترات الصوديوم، ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- يأتي زوميتا في شكل مسحوق في قنينة مع أمبول ماء يُستخدم لإذابة المسحوق أو في صورة سائل مُركز في قنينة، يتم تخفيفه أكثر قبل الاستخدام.</p><p dir="RTL">يتم تقديم زوميتا &quot;الجاهز للاستخدام&quot; كزجاجة.</p><p dir="RTL">قد تختلف هذه المعلومات في بعض البلاد.</p><p dir="RTL">قد لا يتم تسويق جميع العبوات في بلدك</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التَّسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            د. تمت آخر موافقة على هذه النشرة في 11/2022 من قِبل الوكالة السويسرية للمنتجات العلاجية.

هـ. للإبلاغ عن الأعراض الجانبية:

المملكة العربية السعودية

         المركز الوطني للتَّيقظ والسَّلامة الدَّوائية (NPC):

مركز اتصال الهيئة السعودية العامة للغذاء والدَّواء: 19999
البريد الإلكتروني: npc.drug@sfda.gov.sa
الموقع الإلكتروني: https://ade.sfda.gov.sa

 

شركة نوفارتس - السعودية - قسم سلامة المرضى:
الهاتف المجاني: 8001240078
الهاتف: 966112658100+
الفاكس: 966112658107+
البريد الإلكتروني: adverse.events@novartis.com

 

دول مجلس التَّعاون الخليجي الأخرى:

يُرجى الاتصال بسلطات الاختصاص المعنية.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zometa® 4 mg/5 ml
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zoledronic acid (as zoledronic acid monohydrate)
4 mg anhydrous zoledronic acid (as 4.264 mg zoledronic acid monohydrate)
For a full list of excipients, see section 6.1. 


For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vial containing concentrate for solution for infusion.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of adult patients with tumour-induced hypercalcaemia (TIH).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zometa must not be mixed with solutions for infusion containing calcium or other divalent cations (e.g. lactated Ringer&rsquo;s solution) and should be administered as a single intravenous solution in a separate line from all other medicinal products in no less than 15 minutes.</p><p><u>Dosage in adults and elderly patients</u></p><p>The recommended dose is 4 mg zoledronic acid. Zometa concentrate for solution for infusion (4 mg/5 ml) is further diluted with 100 ml of either 0.9% sodium chloride solution or 5% glucose solution and administered as an intravenous infusion. The duration of the infusion must be no less than 15 minutes (see section 4.4).</p><p>The patient&rsquo;s fluid status must be checked before Zometa administration. Fluids should be given according to clinical status.</p><p>Patients with hypercalcaemia of malignancy (albumin-corrected serum calcium &ge;3.0 mmol/l or 12 mg/dl) should be given a single infusion.</p><p>In patients with bone metastases and those with multiple myeloma Zometa should be given every 3 4 weeks. Patients should also receive daily oral doses of 500 mg calcium and 400 IU vitamin D.</p><p><u>Dosage in patients with renal impairment</u></p><p>In patients with hypercalcaemia of malignancy (HCM) and severe renal impairment treatment with Zometa should be considered only after evaluating the benefits and risks of treatment. Clinical studies excluded patients with serum creatinine &ge;400 &micro;mol/l or &ge;4.5 mg/dl. No dose adjustment is necessary in HCM patients with serum creatinine &lt;400 &micro;mol/l or &lt;4.5 mg/dl.</p><p>When initiating treatment in patients with multiple myeloma or bone metastases from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined. CLcr is calculated from serum creatinine using the Cockcroft Gault formula. Zometa is not recommended in patients with severe renal impairment (CLcr &lt;30 ml/min) prior to initiating therapy. Clinical studies of Zometa excluded patients with serum creatinine &gt;265 &micro;mol/l or &gt;3.0 mg/dl.</p><p>In patients with bone metastases and mild to moderate renal impairment (CLcr 30 60 ml/min) prior to initiating therapy the following Zometa doses are recommended:</p><p>Treatment with Zometa is not recommended in patients with CLcr &lt;30 ml/min (see section 4.4). CLcr &gt;60 ml/min: 4.0 mg; CLcr 50 60 ml/min: 3.5 mg; CLcr 40 49 ml/min: 3.3 mg; CLcr 30 39 ml/min: 3.0 mg.</p><p>Doses have been calculated assuming a target AUC of 0.66 (mg&bull;h/l; CLcr = 75 ml/min). The reduced doses for patients with renal impairment are expected to achieve the same AUC as that seen in patients with a creatinine clearance of 75 ml/min.</p><p>After initiating therapy, serum creatinine should be measured prior to each dose of Zometa and treatment should be interrupted if renal function deteriorates.</p><p>In the clinical studies renal deterioration was defined as follows: an increase of &ge;0.5 mg/dl in patients with normal baseline serum creatinine (&lt;1.4 mg/dl) and an increase of &ge;1.0 mg/dl in patients with abnormal baseline serum creatinine (&gt;1.4 mg/dl).</p><p>Treatment with Zometa should only be resumed when creatinine levels are no more than 10% above the baseline value (see section 4.4). Zometa should be resumed at the same dose as prior to treatment interruption.</p><p>Dosage in patients with hepatic impairment</p><p>As no clinical data are available for the treatment of patients with severe hepatic impairment, no specific recommendations can be given for these patients.</p><p><u>Paediatric patients</u></p><p>The safety and efficacy of Zometa have not been studied in children and adolescents.<em> </em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Zometa is contraindicated during pregnancy and breast-feeding (see section 4.6) and in patients with hypersensitivity to zoledronic acid, other bisphosphonates or any of the other components of Zometa. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>General</u></p><p>Adequate hydration of all patients, including those with mild to moderate renal impairment, must be ensured prior to administration of Zometa.</p><p>Hypocalcaemia, hypophosphataemia or hypomagnesaemia should be effectively treated.</p><p>Overhydration must be avoided in patients at risk of cardiac failure.</p><p>Serum levels of albumin-corrected calcium (see section 4.1), phosphate and magnesium, in addition to serum creatinine, should be carefully monitored after initiating Zometa therapy.</p><p>Following thyroid surgery patients may be particularly susceptible to hypocalcaemia as a result of relative hypoparathyroidism.</p><p>Patients with osteolytic bone metastases or with osteolysis in multiple myeloma without hypercalcaemia should receive adequate supplementation of calcium and vitamin D.</p><p>If hypocalcaemia, hypophosphataemia or hypomagnesaemia occurs, short-term supplementation may be necessary. Patients with untreated hypercalcaemia generally have some degree of renal impairment and close monitoring of renal function should therefore be considered.</p><p>Zometa contains the same active substance as Aclasta&reg; (zoledronic acid). Patients treated with Zometa should not be treated with Aclasta concomitantly.</p><p>The decision to treat patients with bone metastases for the prevention of skeletal-related events should take into consideration that the time to onset of treatment effect is 2 3 months.</p><p><u>Renal impairment</u></p><p>In patients with HCM and evidence of renal impairment care should be taken to ensure that the potential benefit of continued treatment with Zometa outweighs the possible risks (see section 4.2)</p><p>If Zometa is infused over a period of less than 15 minutes, the risk of creatinine increase is increased 2 fold. The infusion time should therefore be at least 15 minutes and this should be closely monitored. Although the risk is reduced with a 4 mg dose administered for no less than 15 minutes, deterioration in renal function may still occur. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of Zometa.</p><p>Factors that may increase the probability of renal deterioration include dehydration, pre-existing renal impairment, multiple cycles of Zometa or other bisphosphonates as well as use of nephrotoxic agents or using a shorter infusion time than currently recommended.</p><p>Serum creatinine levels should be measured before each Zometa dose. In patients with bone metastases who have mild to moderate renal impairment lower doses of Zometa are recommended at the start of treatment. Zometa treatment should be resumed at the same dose as that given prior to treatment interruption.. In patients who show evidence of renal deterioration during treatment Zometa should only be resumed when creatinine levels are less than 10% above the baseline value (see section 4.2)</p><p>Zometa has been associated with reports of renal impairment. In a pooled analysis of safety data from Zometa registration studies for the prevention of skeletal-related events in patients with advanced malignancy involving bone, the frequency of renal impairment adverse events suspected to be related to Zometa was as follows: multiple myeloma (3.2%), prostate cancer (3.1%), breast cancer (4.3%), lung and other solid tumours (3.2%).</p><p>The use of Zometa is not recommended in patients with severe renal impairment as there are limited clinical safety and pharmacokinetic data in this population and there is a risk of renal deterioration in patients treated with bisphosphonates, including Zometa. In clinical studies patients with severe renal impairment were defined as those with baseline serum creatinine 400 &micro;mol/l or 4.5 mg/dl. In pharmacokinetic studies patients with severe renal impairment were defined as those with baseline creatinine clearance &lt;30 ml/min (see section 5.2 and 4.2).</p><p><u>Osteonecrosis</u></p><p><u>Osteonecrosis of the jaw</u></p><p>Cases of osteonecrosis of the jaw have been reported predominantly in cancer patients treated with bisphosphonates, including Zometa. Many of these patients were also receiving chemotherapy and corticosteroids or anti-angiogenic medicinal products. Many had signs of local infection, including osteomyelitis.</p><p>Post-marketing experience and the literature suggest a greater frequency of osteonecrosis of the jaw based on tumour type (advanced breast cancer, multiple myeloma), and dental status (dental extraction, periodontal disease, local trauma, including poorly fitting dentures).</p><p>Cancer patients should maintain good oral hygiene and should have a dental examination with appropriate preventive dentistry prior to commencing treatment with bisphosphonates.</p><p>While on treatment with bisphosphonates, these patients should avoid invasive dental procedures if possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy dental surgery may exacerbate the condition. For patients requiring dental treatment there are no data to suggest that interruption of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. The clinical judgement of the attending physician should determine the treatment plan for each individual patient based on a benefit-risk assessment.</p><p><u>Osteonecrosis of other anatomical sites</u></p><p>Cases of osteonecrosis of other anatomical sites, including the hip, femur and external auditory canal have been reported predominantly in adult cancer patients treated with bisphosphonates, including Zometa.</p><p><u>Atypical femoral fractures</u></p><p>Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. These transverse or short oblique fractures can occur anywhere along the femur from just below the lesser trochanter to the condyles. These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. Fractures are often bilateral; therefore, the contralateral femur should also be examined in bisphosphonate-treated patients who have sustained a femoral shaft fracture. Poor healing of these fractures has also been reported. In patients with a suspected atypical femoral fracture discontinuation of bisphosphonate therapy should be considered pending evaluation of the patient based on an individual benefit-risk assessment. Atypical femoral fractures have been reported in tumour patients treated with Zometa.</p><p>During Zometa treatment patients should be advised to report any hip, knee or groin pain; patients with such symptoms should be evaluated for an incomplete femoral fracture.</p><p><u>Hypocalcaemia</u></p><p>Hypocalcaemia has been reported in patients treated with Zometa. Cardiac arrhythmias and neurological adverse events (seizures, tetany and numbness) have been reported secondary to cases of severe hypocalcaemia. In some instances the hypocalcaemia may be life-threatening. Caution is indicated when using Zometa concomitantly with other medicinal products which cause hypocalcaemia as these may have a synergistic effect and result in severe hypocalcaemia (see section 4.5). Serum calcium levels should be measured and hypocalcaemia must be corrected before initiating Zometa therapy. Patients should be given sufficient calcium and vitamin D.</p><p><u>Musculoskeletal pain</u></p><p>In post-marketing experience cases of severe and occasionally incapacitating bone, joint and/or muscle pain have been reported during use of bisphosphonates (including zoledronic acid). In some cases this pain occurred within the first day and in other cases several months after starting treatment. In most cases the pain was reversible on discontinuing the medicinal product. Some patients experienced a recurrence of symptoms upon re-initiation of the same or another bisphosphonate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caution is required when administering bisphosphonates concomitantly with aminoglycosides, calcitonin or loop diuretics since these substance classes may have an additive calcium-lowering effect, resulting in lowered serum calcium levels for longer periods than required (see section 4.4).</p><p>Caution is required when Zometa is given with other medicinal products that may also impair renal function (see section 4.8).</p><p>Caution is indicated when Zometa is co-administered with angiogenesis inhibitors as an increased frequency of osteonecrosis of the jaw has been observed in patients treated concomitantly with these medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Fertility</u></p><p>Fertility was decreased in rats dosed subcutaneously with 0.01 mg/kg/day of zoledronic acid. There are no data available in humans.</p><p><strong>&nbsp;</strong></p><p><u>Pregnancy/Breast-feeding</u></p><p><u>Women of childbearing potential</u></p><p>There is a potential risk of fetal harm (e.g. skeletal and other abnormalities) if a woman becomes pregnant during treatment with a bisphosphonate (see &ldquo;Contraindications&rdquo;). Women of child-bearing potential must use a reliable method of contraception during treatment with Zometa if treatment is unavoidable or cannot be delayed. Zoledronic acid is deposited in the bone matrix and is gradually released again after the end of treatment. This may last weeks to years. The volume of the amount released is dependent on the overall dose administered. The systemic exposure from this release is not known and the resulting risk for pregnancy cannot be estimated.</p><p><u>Pregnancy</u></p><p>Studies in rats have shown reproductive toxicity (see section 4.8). The potential risk in humans is unknown.</p><p>Zometa must not be used during pregnancy (see &ldquo;Contraindications&rdquo;).</p><p><u>Breast-feeding</u></p><p>There is no experience in breast-feeding women. Zometa should therefore not be used in such patients (see &ldquo;Contraindications&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data are available regarding effects on the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile</p><p>The most serious adverse reactions reported in patients on Zometa treatment in the approved indications are: anaphylactic reaction, ocular adverse effects, osteonecrosis of the jaw, atypical femoral fracture, atrial fibrillation, renal impairment, acute phase reaction and hypocalcaemia.</p><p>The adverse effects of Zometa are similar to those reported for other bisphosphonates and can be expected to occur in approximately one third of patients. The most frequent are influenza-like symptoms, including bone pain (9.1%), pyrexia (7.2%), fatigue (4.1%), chills (2.9%), arthralgia and myalgia (approx. 3%) and arthritis with associated joint swelling. These adverse effects usually resolve within a few days.</p><p>An acute phase reaction is associated with various symptoms such as influenza-like symptoms, fatigue, pyrexia, chills and bone pain. The onset of these symptoms generally occurs within 3 days of infusion of zoledronic acid. They usually resolve within a few days. These symptoms are also referred to as &ldquo;flu-like&rdquo; or &ldquo;post-dose&rdquo; symptoms.</p><p>Very commonly, the reduction in urinary calcium excretion is accompanied by an asymptomatic decrease in serum phosphate levels not requiring treatment. Serum calcium may often fall to asymptomatic hypocalcaemic levels.</p><p><em><u>b. Tabulated summary of adverse reactions </u></em></p><p>Adverse effects are listed according to frequency. The most frequent are listed first. The following descriptions are used:</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), including isolated cases.</p><p><u>Blood and lymphatic system disorders</u></p><p><strong>Common:</strong> Anaemia.</p><p><strong>Uncommon: </strong>Thrombocytopenia, leukopenia.</p><p><strong>Rare: </strong>Pancytopenia.</p><p><u>Immune system disorders</u></p><p><strong>Uncommon: </strong>Hypersensitivity reactions, urticaria, anaphylactic reaction/shock.</p><p><strong>Rare:</strong> Angioedema</p><p><u>Metabolism and nutrition disorders</u></p><p><strong>Very common:</strong> Hypophosphataemia.</p><p><strong>Common:</strong> Hypocalcaemia.</p><p><strong>Uncommon:</strong> Hypomagnesaemia, hypokalaemia.</p><p><strong>Rare:</strong> Hyperkalaemia, hypernatraemia.</p><p><u>Psychiatric disorders</u></p><p><strong>Common: </strong>Sleep disorders</p><p><strong>Uncommon:</strong> Restlessness, anxiety.</p><p><strong>Rare:</strong> Confusional state.</p><p><u>Nervous system disorders</u></p><p><strong>Common:</strong> Headache, paraesthesia.</p><p><strong>Uncommon:</strong> Dizziness, dysgeusia, hypoaesthesia, hyperaesthesia, tremor, somnolence.</p><p><strong>Very rare:</strong> Convulsions, hypoaesthesia and tetany (secondary to hypocalcaemia).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Eye disorders</u></p><p><strong>Common: </strong>Conjunctivitis</p><p><strong>Uncommon:</strong> Blurred vision, scleritis, orbital inflammation.</p><p><strong>Rare:</strong> Uveitis</p><p><strong>Very rare:</strong> Episcleritis.</p><p><u>Cardiac disorders</u></p><p><strong>Uncommon:</strong> Atrial fibrillation</p><p><strong>Rare: </strong>Bradycardia, cardiac arrhythmia (secondary to hypocalcaemia).&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Vascular disorders</u></p><p><strong>Common: </strong>Hypertension</p><p><strong>Uncommon: </strong>Hypotension, orthostatic hypotension, including syncope/circulatory collapse.</p><p><u>Respiratory, thoracic and mediastinal disorders</u></p><p><strong>Uncommon: </strong>Dyspnoea, cough.</p><p><strong>Rare:</strong> Interstitial lung disease</p><p><strong>Very rare: </strong>Bronchospasm.</p><p><u>Gastrointestinal disorders</u></p><p><strong>Common: </strong>Nausea, vomiting, decreased appetite, constipation.</p><p><strong>Uncommon:</strong> Diarrhoea, abdominal pain, dyspepsia, stomatitis, dry mouth.</p><p><u>Skin and subcutaneous tissue disorders</u></p><p><strong>Common: </strong>Increased sweating.</p><p><strong>Uncommon: </strong>Pruritus, rash (including erythematous and macular rash).</p><p><u>Musculoskeletal and connective tissue disorders</u></p><p><strong>Common:</strong> Bone pain, myalgia, arthralgia, joint stiffness.</p><p><strong>Uncommon:</strong> Muscle spasms, osteonecrosis of the jaw (see section 4.4).&nbsp;</p><p><strong>Rare: </strong>Atypical subtrochanteric and diaphyseal femoral fractures, arthritis and joint swelling as symptoms of an acute phase reaction.</p><p><strong>Very rare: </strong>Osteonecrosis of other anatomical sites</p><p><u>Renal and urinary disorders</u></p><p><strong>Common: </strong>Renal impairment, increased serum creatinine and serum urea.</p><p><strong>Uncommon:</strong> Acute renal failure, haematuria, proteinuria.</p><p><strong>Rare: </strong>Acquired Fanconi syndrome</p><p><u>General disorders and administration site conditions</u></p><p><strong>Common:</strong> Generalised pain, acute phase reaction, pyrexia, influenza-like symptoms (including fatigue, chills, malaise and flushing), peripheral oedema, asthenia.</p><p><strong>Uncommon:</strong> Infusion site reactions (including pain, irritation, swelling, induration, redness), chest pain, weight gain.</p><p>&nbsp;</p><p>Reporting suspected adverse effects after authorisation of the medicinal product is very important. It allows continued monitoring of the risk-benefit ratio of the medicinal product. Healthcare professionals are asked to report any suspected new or serious adverse effects.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o Fax: +966-11-205-7662</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical experience with acute overdose of Zometa is limited. Patients who have received a higher than recommended dose should be carefully monitored since renal impairment (including renal failure) and serum electrolyte (including calcium, phosphorus and magnesium) abnormalities have been observed. In the event of hypocalcaemia calcium gluconate infusions should be administered as clinically indicated.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code</p><p>M05 BA 08</p><p>Mechanism of action</p><p>Zoledronic acid is a bisphosphonate which acts primarily on bone. Zoledronic acid is an inhibitor of bone resorption caused by increased osteoclastic activity.</p><p>The selective action of bisphosphonates on bone tissue is based on their high affinity for mineralised bone.</p><p>The molecular mechanism of action is still unclear. In long-term animal studies zoledronic acid inhibited bone resorption without adversely affecting the regeneration, mineralisation or mechanical properties of bone.</p><p>Pharmacodynamics</p><p>See &ldquo;Mechanism of action&rdquo;.</p><p>Clinical efficacy</p><p>Clinical efficacy in patients with solid tumours and multiple myeloma</p><p>Bone metastases</p><p>In a double-blind, randomised phase III study 4 mg Zometa was compared with 90 mg pamidronate. 1,122 patients with multiple myeloma or breast cancer and at least one bone lesion were treated with 4 mg Zometa (564 patients) or 90 mg pamidronate (558 patients) every 3 4 weeks. The primary endpoint was the proportion of patients with at least one skeletal-related event (SRE; vertebral fractures, non-vertebral fractures, spinal cord compression, bone radiotherapy, bone surgery). The number of patients with an SRE was 44% with Zometa and 46% with pamidronate (95% confidence interval -7.9%, 3.7%). 606 patients were treated for an additional 12 months.</p><p>The results of the overall analysis of the core and extension data showed the efficacy of 4 mg Zometa to be at least comparable to that of 90 mg pamidronate in the prevention of SREs: the number of SREs was 48% with Zometa and 52% with pamidronate (95% confidence interval -9.3%, 2.5%). Multiple-event analysis showed an additional 16% risk reduction in the Zometa group compared to the pamidronate group (p=0.03).</p><p>A 15 month study in prostate cancer patients (214 men receiving 4 mg Zometa and 208 receiving placebo) showed a significant advantage for Zometa over placebo, both in the number of patients experiencing at least one SRE (33% with 4 mg Zometa vs 44% with placebo; p=0.021) and in the median time to first SRE (risk ratio 0.672 [0.492, 0.918]; p=0.012).</p><p>186 patients were treated for an additional 9 months. SRE rates were 38% on Zometa vs 49% on placebo (p=0.028). 4 mg Zometa also delayed median time to first SRE (488 days on 4 mg Zometa vs 321 days on placebo; p=0.009). In addition, Zometa reduced the annual number of SREs (skeletal morbidity rate) per patient (0.77 on Zometa vs 1.47 on placebo; p=0.005). Multiple-event analysis showed a 36% reduction in the risk of SREs in the Zometa group compared with placebo (p=0.002). Pain was measured at the start of treatment and periodically throughout the study. Patients receiving Zometa reported less of an increase in pain than those receiving placebo. The difference was significant after 3, 9, 21 and 24 months. Fewer Zometa patients suffered pathological fractures. The treatment effects were less pronounced in patients with blastic lesions.</p><p>Zometa was compared with placebo in a 9-month study involving 407 patients with other types of solid tumour and bone metastases. 101 patients were included in the extension study and 26 were treated for a total of 21 months. After 9 months there was a significantly prolonged interval to the first SRE (p=0.03), but no significant difference compared with placebo in the number of patients with SREs. 38% of Zometa patients vs 44% in the placebo group had at least one SRE (+ HCM) after 9 months (p=0.127), with corresponding figures of 39% vs 48% at the end of the extension period (p=0.039).</p><p>Median time to first SRE was 236 days for Zometa vs 155 days for placebo (p=0.009) and the annual number of SREs per patient (skeletal morbidity rate) was 1.74 for Zometa vs 2.71 for placebo (p=0.012). Multiple-event analysis showed a 30.7% reduced risk of SREs in the Zometa group compared with placebo (p=0.003). The treatment effect in NSCLC patients appeared to be smaller than in patients with other solid tumours.</p><p>While no substantial effect on bone pain was documented in the above-mentioned studies, this was demonstrated in a study conducted in Japan involving 228 women with breast cancer and bone metastases. This was a double-blind, placebo-controlled study in which either 4 mg Zometa or placebo was administered over 48 weeks. The ratio of skeletal complications for Zometa versus placebo was 0.61 (p=0.027). In patients treated with Zometa an improvement in bone pain was observed in the Brief Pain Inventory (BPI) from 4 weeks after the start of treatment.</p><p>Hypercalcaemia</p><p>Comparative studies with pamidronate have demonstrated that in tumour-induced hypercalcaemia, zoledronic acid lowers serum calcium and urinary calcium excretion.</p><p>Complete response rates after 10 days were 88.4% for Zometa and 69.7% for pamidronate. The difference between Zometa and pamidronate was statistically significant.</p><p>In half of all cases elevated serum calcium can be lowered to within the normal range within 4 days by a single infusion of Zometa. The median time to recurrence of hypercalcaemia was 30 40 days on Zometa versus 20 22 days on pamidronate.</p><p>The complete response rate to re-treatment for a reincrease in corrected serum calcium &gt;2.9 mmol/l was approximately 52%.</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB style='color:black'><v:shape id="_x0000_i1025" type="#_x0000_t75"
 style='width:481.95pt;height:327.95pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>After the infusion of zoledronic acid is initiated, plasma concentrations of the active substance increase rapidly, reaching a peak at the end of the infusion period. This is followed by a rapid decline to &lt;10% of peak plasma concentrations after 4 h and &lt;1% after 24 h, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak plasma concentrations prior to the second infusion of active substance on day 28.</p><p>Distribution</p><p>Within the first 24 h, 39  16% of the administered dose is recovered in the urine. The remainder is bound to bone tissue.</p><p>Zoledronic acid shows little affinity for human blood cells at a mean blood/plasma concentration ratio of 0.59 in a concentration range of 30 ng/ml to 5000 ng/ml.&nbsp; Plasma protein binding is low with an unbound fraction in the range of 60% at 2 ng/ml to 77% at 2000 ng/ml zoledronic acid.</p><p>Increasing the infusion time from 5 to 15 min causes a 30% decrease in zoledronic acid concentration at the end of the infusion, but has no effect on the AUC.</p><p>As with other bisphosphonates, interpatient variability in the pharmacokinetic parameters for zoledronic acid is high.</p><p>Metabolism</p><p>Zoledronic acid does not inhibit human P450 enzymes in vitro and is not metabolised. Zoledronic acid is excreted unchanged via the kidneys. It is very slowly released from the bone tissue back into the systemic circulation and is eliminated via the kidneys with a half-life (t1/2) of at least 146 h. Total body clearance is 5.04 &plusmn; 2.5 l/h, irrespective of dosage.</p><p>Elimination</p><p>Intravenously administered zoledronic acid is eliminated in two phases: rapid biphasic elimination from the systemic circulation with half-lives of 0.24 h (t1/2) and 1.8 h (t1/2), followed by a long elimination phase. There is no accumulation of the active substance in the plasma, even after multiple doses (every 28 days).</p><p>In animal studies &lt;3% of the administered dose was recovered in the faeces.</p><p>Linearity/non-linearity</p><p>The pharmacokinetics of zoledronic acid are dose independent.</p><p>Pharmacokinetics in special populations</p><p>Patients with hypercalcaemia: No pharmacokinetic data on zoledronic acid are available in patients with hypercalcaemia.</p><p>Patients with hepatic impairment: No pharmacokinetic data on zoledronic acid are available in patients with hepatic impairment. Zoledronic acid does not inhibit human P450 enzymes in vitro and is not metabolised. In animal studies &lt;3% of the administered dose was recovered in the faeces. This suggests that hepatic function plays no relevant role in the pharmacokinetics of zoledronic acid.</p><p>Patients with renal impairment: The renal clearance of zoledronic acid correlates with creatinine clearance. Renal clearance corresponds to 75  33% of creatinine clearance, which showed a mean of 84  29 ml/min (from 22 to 143 ml/min) in the 64 tumour patients studied. Population analysis showed that for a patient with a creatinine clearance of 20 ml/min (severe renal impairment) or 50 ml/minute (moderate renal impairment), the predicted clearance of zoledronic acid would be 37% and 72%, respectively, of that in a patient with a creatinine clearance of 84 ml/min. The use of Zometa is not recommended in patients with severe renal impairment (see section 4.4).</p><p>Effect of gender, age and race</p><p>The three pharmacokinetic studies conducted in cancer patients with bone metastases do not indicate any influence of gender, race, age (38 84 years) or body weight on total zoledronic acid clearance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp; Toxicological studies</p><p>In the bolus studies zoledronic acid was well tolerated when administered subcutaneously to rats and intravenously to dogs at doses of up to 0.02 mg/kg daily for 4 weeks. Administration of 0.001 mg/kg/day subcutaneously in rats and 0.005 mg/kg intravenously once every 2 to 3 days in dogs for up to 52 weeks was also well tolerated. Renal toxicity studies were conducted in rats and dogs. Intravenous infusion with doses of up to 0.6 mg/kg in rats and up to 0.25 mg/kg in dogs was well tolerated but dosing intervals were different.</p><p>The most frequent finding in the repeat-dose studies consisted of increased primary spongiosa in the metaphyses of long bones in growing animals at nearly all doses, a finding that reflected the compound&rsquo;s pharmacological antiresorptive activity.</p><p>The kidney was identified as the main target organ for toxicity with parenteral administration of zoledronic acid.</p><p>&nbsp;</p><p>Reproductive toxicity</p><p>In a study on fertility and embryonic development fertility was decreased in rats dosed subcutaneously with 0.01 mg/kg/day of zoledronic acid. Pre- and post-implantation losses were observed at a dose of 0.03 mg/kg/day. At a dose of 0.01 mg/kg/day dystocia, difficult parturition and maternal peripartum mortality were observed. At a dose of 0.1 mg/kg/day the viability and body weight of the offspring was reduced.</p><p>Teratogenicity studies involving subcutaneous administration of zoledronic acid were performed in two species. Teratogenicity was observed in rats at maternally toxic doses of &ge;0.2 mg/kg/day, manifesting as external, visceral and skeletal malformations. Skeletal variations even occurred at the lowest dose of 0.1 mg/kg/day.</p><p>Maternally toxic effects such as abortion and mortality occurred in rabbits at a dose of 0.1 mg/kg/day, which may be connected to drug-induced hypocalcaemia. No teratogenic or fetotoxic effects were observed in rabbits. The number of evaluable fetuses was low due to the above-mentioned maternal toxicity.</p><p>Mutagenicity</p><p>Zoledronic acid was not mutagenic in the in vitro and in vivo mutagenicity tests performed.</p><p>Carcinogenicity</p><p>Carcinogenicity studies in rodents did not provide any evidence of carcinogenic potential. Zoledronic acid was, however, administered orally and the systemic exposure of the animals is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Sodium citrate</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Studies with glass bottles as well as various infusion bags and infusion lines made of polyvinyl chloride, polyethylene and polypropylene (pre-filled with 0.9% sodium chloride solution or 5% glucose solution) showed no incompatibility with Zometa.</p><p>To avoid potential incompatibilities, Zometa concentrate for solution for infusion should only be diluted with 0.9% sodium chloride solution or 5% glucose solution.</p><p>Zometa must not be mixed with solutions for infusion containing calcium or other divalent cations (e.g. lactated Ringer&rsquo;s solution) and should be administered as a single intravenous solution in a separate line from all other medicinal products.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
After dilution: From a microbiological point of view, the diluted solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C – 8°C. The refrigerated solution should then be equilibrated to room temperature prior to administration.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p><p>For storage conditions of the reconstituted solution for infusion, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unit packs containing 1 or 4 vials.</p><p>Multi-packs containing 10 (10 packs of 1) vials.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Zometa 4 mg/5 ml concentrate for solution for infusion is for intravenous use only. The 5 ml from one vial, or the amount of concentrate for solution for infusion withdrawn for the indicated dose, should be diluted with 100 ml of a calcium-free solution for infusion (0.9% sodium chloride solution or 5% glucose solution; see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by Swissmedic in November 2022.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>